Nuvation Bio (NUVB)
Develops cancer medicines led by IBTROZI and a focused oncology pipeline.
Something off on this page? Send us feedback.
Sells IBTROZI in the US for ROS1-positive lung cancer while advancing safusidenib in IDH1-mutant glioma and a DDC program. The business shifted after the AnHeart acquisition and currently depends on U.S. IBTROZI sales, collaboration and licensing economics, and continued oncology trial execution.
Develops and commercializes oncology medicines, with IBTROZI / taletrectinib as the commercial anchor for ROS1-positive non-small cell lung cancer. The current portfolio also includes safusidenib in IDH1-mutant glioma and an earlier drug-drug conjugate program.
Moved into commercial-stage oncology through the AnHeart acquisition, then launched IBTROZI in the United States after FDA approval. Collaboration, supply, royalty, and licensing economics extend the taletrectinib business outside the U.S.
Execution depends on IBTROZI adoption, continued clinical progress for safusidenib, regulatory outcomes, safety data, and launch financing. Product revenue is currently concentrated in U.S. IBTROZI sales.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 21, 2026 | Cantor Fitzgerald | Initiate | Rating: — | |
| Aug 7, 2026 | RBC Capital | Reiterate | Rating: —Target: $19 | Target: $20 |
| Jul 27, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $17 | Target: $21 |
| Jul 7, 2026 | RBC Capital | Reiterate | Rating: —Target: $12 | Target: $19 |
| Jan 27, 2026 | Truist Financial | Target | Target: $11 | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $661.0M · Total debt $252.1M · Total assets $744.5M · Shareholders' equity $253.9M
- Revenue
- $31.7M
- Operating income
- −$51.0M
- Net income
- −$62.8M
No dividends on record.
| Institutions | ≈ 66.55% | 233.67M shares | |
|---|---|---|---|
| 251 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 25.72% | 90.30M shares | |
| 11 holders · as of Jul 17, 2026 | |||
| Other | ≈ 7.73% | 27.15M shares | |
| remainder | |||
351.12M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
David Hung1Insiderdirector, 10 percent owner, officer: PRESIDENT AND CEO | 16.88% | 59.28M | filed Jun 18, 2025 |
FMR LLCInstitution | 14.88% | 52.23M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.87% | 27.63M | as of Jun 30, 2026 |
Xiangmin CuiInsider | 7.58% | 26.60M | filed Sep 10, 2024 |
Decheng Capital LLCInstitution | 7.39% | 25.95M | as of Jun 30, 2026 |
- David Hung reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Gary Hattersley | officer: CHIEF SCIENTIFIC OFFICER | −100,000 | $7.09 |
| Jun 23, 2026 | Philippe Sauvage | officer: Chief Financial Officer | −47,668 | $6.01 |
| Jun 23, 2026 | Kerry Wentworth | officer: CHIEF REGULATORY OFFICER | −63,000 | $6.02 |
| Jun 23, 2026 | Stacy Markel | officer: CHIEF PEOPLE OFFICER | −125,000 | $6.03 |
| Jun 9, 2026 | Robert Mashal | director | +25,000 | $4.73 |
- Bristol-Myers Squibb
Approved next-generation ROS1 therapy in the same NSCLC setting
- Pfizer
First-generation ROS1 standard with long-standing FDA approval
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nuvation Bio | $6.11 | +0.16% | $2.11B | — | — | 12.4 | +555.6% |
| Bristol-Myers Squibb | $62.31 | +0.10% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Pfizer | $27.89 | −0.14% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Median | 25.2 | 9.9 | 2.5 | +4.2% |